Qiang Zhao
Director/Board Member bei Shanghai Haihe Biopharma Co., Ltd.
Profil
Qiang Zhao is an Independent Director at Shanghai Haihe Biopharma Co., Ltd.
since 2020.
Prior to this, he held the position of Independent Director at Jionto Energy Investment Co., Ltd.
Hebei.
He also served as an Independent Director at Beijing Chieftain Control Engineering Technology Co., Ltd.
from 2017 to 2023.
Aktive Positionen von Qiang Zhao
| Unternehmen | Position | Beginn |
|---|---|---|
Shanghai Haihe Biopharma Co., Ltd.
 Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | Director/Board Member | 08.09.2020 |
Ehemalige bekannte Positionen von Qiang Zhao
| Unternehmen | Position | Ende |
|---|---|---|
| BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. | Director/Board Member | 10.06.2023 |
| JOINTO ENERGY INVESTMENT CO., LTD. HEBEI | Director/Board Member | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| JOINTO ENERGY INVESTMENT CO., LTD. HEBEI | Utilities |
| BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. | Producer Manufacturing |
| Private Unternehmen | 1 |
|---|---|
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | Commercial Services |
